U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H31FO6
Molecular Weight 434.4977
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXAMETHASONE ACETATE ANHYDROUS

SMILES

[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C

InChI

InChIKey=AKUJBENLRBOFTD-RPRRAYFGSA-N
InChI=1S/C24H31FO6/c1-13-9-18-17-6-5-15-10-16(27)7-8-21(15,3)23(17,25)19(28)11-22(18,4)24(13,30)20(29)12-31-14(2)26/h7-8,10,13,17-19,28,30H,5-6,9,11-12H2,1-4H3/t13-,17+,18+,19+,21+,22+,23+,24+/m1/s1

HIDE SMILES / InChI

Molecular Formula C24H31FO6
Molecular Weight 434.4977
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/67018038

Dexamethasone acetate (NEOFORDEX®) is the acetate salt form of dexamethasone, which is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. At high doses (e.g. 40 mg), it reduces the immune response. Dexamethasone acetate (NEOFORDEX®) is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products. Dexamethasone has been shown to induce multiple myeloma cell death (apoptosis) via a down-regulation of nuclear factor-κB activity and an activation of caspase-9 through second mitochondria-derived activator of caspase (Smac; an apoptosis promoting factor) release. Prolonged exposure was required to achieve maximum levels of apoptotic markers along with increased caspase-3 activation and DNA fragmentation. Dexamethasone also down-regulated anti apoptotic genes and increased IκB-alpha protein levels. Dexamethasone apoptotic activity is enhanced by the combination with thalidomide or its analogues and with proteasome inhibitor (e.g. bortezomib).

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
MAXIDEX

Approved Use

Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.

Launch Date

-2.37859193E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.37859193E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
Neofordex

Approved Use

Neofordex is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products.

Launch Date

1.45799997E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
9.87 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
51.2 ng × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.93 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
30%
DEXAMETHASONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
96 mg multiple, oral (total)
Dose: 96 mg
Route: oral
Route: multiple
Dose: 96 mg
Sources:
unhealthy, 63 years (range: 30–78 years)
n = 21
Health Status: unhealthy
Age Group: 63 years (range: 30–78 years)
Sex: M+F
Population Size: 21
Sources:
0.1 % 3 times / day multiple, ophthalmic
Dose: 0.1 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 0.1 %, 3 times / day
Sources:
unhealthy, 68.3 years (range: 51.0 - 83.0 years)
n = 77
Health Status: unhealthy
Age Group: 68.3 years (range: 51.0 - 83.0 years)
Sex: M+F
Population Size: 77
Sources:
Other AEs: Corneal erosion...
Other AEs:
Corneal erosion (10%)
Sources:
0.6 mg/kg single, oral
Dose: 0.6 mg/kg
Route: oral
Route: single
Dose: 0.6 mg/kg
Sources:
unhealthy, children
n = 6
Health Status: unhealthy
Condition: Migraine
Age Group: children
Population Size: 6
Sources:
Other AEs: Constipation...
Other AEs:
Constipation (below serious, 1 patient)
Sources:
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
n = 106
Health Status: unhealthy
Condition: Migraine
Population Size: 106
Sources:
Other AEs: Drowsiness, Dizziness...
Other AEs:
Drowsiness (below serious, 19 patients)
Dizziness (below serious, 3 patients)
Adverse drug reaction NOS (below serious, 10 patients)
Sources:
12 mg 1 times / day multiple, intravenous
Dose: 12 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Knee Arthroplasty
Population Size: 10
Sources:
Other AEs: Wound dehiscence...
Other AEs:
Wound dehiscence (below serious, 1 patient)
Sources:
20 mg single, intravenous
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
unhealthy
Health Status: unhealthy
Sources:
24 mg 1 times / day multiple, intravenous
Dose: 24 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Knee Arthroplasty
Population Size: 10
Sources:
Other AEs: Dizziness...
Other AEs:
Dizziness (below serious, 1 patient)
Sources:
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Other AEs: Constipation, Dyspepsia...
Other AEs:
Constipation (below serious, 47 patients)
Dyspepsia (below serious, 12 patients)
Vomiting (below serious, 9 patients)
Fatigue (below serious, 58 patients)
Cholesterol high (below serious, 8 patients)
Anorexia (below serious, 15 patients)
Anxiety (below serious, 11 patient)
Insomnia (below serious, 26 patients)
Cough (below serious, 9 patients)
Dyspnea (below serious, 20 patients)
Sources:
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Other AEs: Incision site bleeding, Body temperature decrease...
Other AEs:
Incision site bleeding (below serious, 1 patient)
Body temperature decrease (below serious, 2 patients)
Shivering (below serious, 1 patient)
Tachycardia (below serious, 1 patient)
Transfusion (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Corneal erosion 10%
0.1 % 3 times / day multiple, ophthalmic
Dose: 0.1 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 0.1 %, 3 times / day
Sources:
unhealthy, 68.3 years (range: 51.0 - 83.0 years)
n = 77
Health Status: unhealthy
Age Group: 68.3 years (range: 51.0 - 83.0 years)
Sex: M+F
Population Size: 77
Sources:
Constipation below serious, 1 patient
0.6 mg/kg single, oral
Dose: 0.6 mg/kg
Route: oral
Route: single
Dose: 0.6 mg/kg
Sources:
unhealthy, children
n = 6
Health Status: unhealthy
Condition: Migraine
Age Group: children
Population Size: 6
Sources:
Adverse drug reaction NOS below serious, 10 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
n = 106
Health Status: unhealthy
Condition: Migraine
Population Size: 106
Sources:
Drowsiness below serious, 19 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
n = 106
Health Status: unhealthy
Condition: Migraine
Population Size: 106
Sources:
Dizziness below serious, 3 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
n = 106
Health Status: unhealthy
Condition: Migraine
Population Size: 106
Sources:
Wound dehiscence below serious, 1 patient
12 mg 1 times / day multiple, intravenous
Dose: 12 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Knee Arthroplasty
Population Size: 10
Sources:
Dizziness below serious, 1 patient
24 mg 1 times / day multiple, intravenous
Dose: 24 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Knee Arthroplasty
Population Size: 10
Sources:
Anxiety below serious, 11 patient
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Dyspepsia below serious, 12 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Anorexia below serious, 15 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Dyspnea below serious, 20 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Insomnia below serious, 26 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Constipation below serious, 47 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Fatigue below serious, 58 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Cholesterol high below serious, 8 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Cough below serious, 9 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Vomiting below serious, 9 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Incision site bleeding below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Shivering below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Tachycardia below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Transfusion below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Body temperature decrease below serious, 2 patients
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: These data demonstrate that dexamethasone at doses used clinically increased CYP3A4 activity with extensive intersubject variability and that the extent of CYP3A4 induction was, in part, predicted by the baseline activity of CYP3A4 in both healthy volunteers and human hepatocyte cultures.
Page: -
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
ECC-1 human endometrial cells as a model system to study dioxin disruption of steroid hormone function.
1999 Apr
Functional assay of NF-kappaB translocation into nuclei by laser scanning cytometry: inhibitory effect by dexamethasone or theophylline.
1999 Apr
Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach.
1999 Dec
Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors.
1999 Dec 24
Dexamethasone induced alterations in the levels of proteases involved in blood pressure homeostasis and blood coagulation in rats.
1999 Jul
Inhibition of gelatinase activity in human airway epithelial cells and fibroblasts by dexamethasone and beclomethasone.
1999 Jul
Platelet-activating factor receptor mRNA is localized in eosinophils and epithelial cells in rat small intestine: regulation by dexamethasone and gut flora.
1999 Jul
Effects of inhaled beclomethasone compared to systemic dexamethasone on lung inflammation in preterm infants at risk of chronic lung disease.
1999 Jun
Induction of stromelysin gene expression by tumor necrosis factor alpha is inhibited by dexamethasone, salicylate, and N-acetylcysteine in synovial fibroblasts.
1999 Jun
Intestinal damage induced by zinc deficiency is associated with enhanced CuZn superoxide dismutase activity in rats: effect of dexamethasone or thyroxine treatment.
1999 May
Dexamethasone therapy increases infection in very low birth weight infants.
1999 Nov
Antenatal dexamethasone suppresses tumor necrosis factor-alpha expression in hypoplastic lung in nitrofen-induced diaphragmatic hernia in rats.
1999 Nov
Dual action of nitric oxide in pathogenesis of indomethacin-induced small intestinal ulceration in rats.
1999 Sep
Morphine induced allodynia in a child with brain tumour.
1999 Sep 4
Antenatal dexamethasone improves atrial natriuretic peptide receptors in hypoplastic lung in nitrofen-induced diaphragmatic hernia in rats.
2000
Dexamethasone suppresses tumor necrosis factor-alpha-induced apoptosis in osteoblasts: possible role for ceramide.
2000 Aug
Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.
2000 Aug
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.
2000 Aug 1
Effect of endogenous and exogenous prostaglandin E(2) on interleukin-1 beta-induced cyclooxygenase-2 expression in human airway smooth-muscle cells.
2000 Dec
Prenatal exposure to high levels of glucocorticoids increases the susceptibility of cerebellar granule cells to oxidative stress-induced cell death.
2000 Dec 19
Effect of polyunsaturated fatty acids on dexamethasone-induced gastric mucosal damage.
2000 Feb
Antenatal dexamethasone enhances endothelin receptorB expression in hypoplastic lung in nitrofen-induced diaphragmatic hernia in rats.
2000 Feb
Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats.
2000 Feb
Administration of antenatal glucocorticoids upregulates peptide growth factor gene expression in nitrofen-induced congenital diaphragmatic hernia in rats.
2000 Jan
Dexamethasone blocks sepsis-induced protection of the heart from ischemia reperfusion injury.
2000 Jan
Acrylamide-regulated neurofilament expression in rat pheochromocytoma cells.
2000 Jan 10
Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review.
2000 Jul 29
Dexamethasone induced cardiac hypertrophy in newborn rats is accompanied by changes in myosin heavy chain phenotype and gene transcription.
2000 Jun
Combined administration of G-CSF and dexamethasone for the mobilization of granulocytes in normal donors: optimization of dosing.
2000 Jun
Down-regulation of thyroid transcription factor-1 gene expression in fetal lung hypoplasia is restored by glucocorticoids.
2000 Jun
Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding.
2000 Jun 23
beta(3)-adrenoceptor regulation and relaxation responses in mouse ileum.
2000 Mar
Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line.
2000 Mar
Regulation of vitamin D-1alpha-hydroxylase and -24-hydroxylase expression by dexamethasone in mouse kidney.
2000 Mar
Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone.
2000 Mar 1
Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism.
2000 May
Regulation of leptin release by troglitazone in human adipose tissue.
2000 Nov
Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis.
2000 Nov 10
Dexamethasone-induced cardiogenic shock rescued by percutaneous cardiopulmonary support (PCPS) in a patient with pheochromocytoma.
2000 Oct
Antenatal dexamethasone enhances surfactant protein synthesis in the hypoplastic lung of nitrofen-induced diaphragmatic hernia in rats.
2000 Oct
Role of caspases in dexamethasone-induced apoptosis and activation of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase in human eosinophils.
2000 Oct
Endotoxin augments cerebral hyperemic response to halothane by inducing nitric oxide synthase and cyclooxygenase.
2000 Oct
Endocrinologic and psychological effects of short-term dexamethasone in anorexia nervosa.
2000 Sep
Involvement of tyrosine hydroxylase up regulation in dexamethasone-induced hypertension of rats.
2000 Sep 8
Intractable nausea attributable to isolated deficiency of adrenocorticotropic hormone: prompt resolution after administration of glucocorticoid.
2000 Sep-Oct
Molecular and pharmacological evidence for modulation of kinin B(1) receptor expression by endogenous glucocorticoids hormones in rats.
2001 Jan
Short term effects of corticosteroid pulse treatment on disease activity and the wellbeing of patients with active rheumatoid arthritis.
2001 Jan
Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen.
2001 Jan
Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network.
2001 Jan 11
Topical 0.1% indomethacin solution versus topical 0.1% dexamethasone solution in the prevention of inflammation after cataract surgery. The Study Group.
2001 Jan-Feb
Patents

Sample Use Guides

One or two drops topically in the conjunctival sac(s). In severe disease, drops may be used hourly. In mild disease, drops may be used up to four to six times daily.
Route of Administration: Other
Caco-2 cells were treated with 1 μM dexamethasone and SGK1 mRNA levels were determined by Northern blot analysis. Figure 1A shows that dexamethasone rapidly induced SGK1 mRNA expression as early as 30 min and maintained the elevated expression for at least 24 h.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:09:28 UTC 2023
Edited
by admin
on Fri Dec 15 16:09:28 UTC 2023
Record UNII
K7V8P532WP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEXAMETHASONE ACETATE ANHYDROUS
Common Name English
DECADRONAL
Brand Name English
NSC-39471
Code English
DEXAMETHASONE ACETATE [USP-RS]
Common Name English
Dexamethasone acetate [WHO-DD]
Common Name English
DEXAMETHASONE ACETATE [USP MONOGRAPH]
Common Name English
DEXAMETHASONE IMPURITY G [EP IMPURITY]
Common Name English
DEXAMETHASONE 21-ACETATE [MI]
Common Name English
DEXAMETHASONI ACETAS [WHO-IP LATIN]
Common Name English
9-FLUORO-11.BETA.,17,21-TRIHYDROXY-16.ALPHA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE 21-ACETATE
Systematic Name English
DEXAMETHASONE ACETATE [EP MONOGRAPH]
Common Name English
DEXAMETHASONE ACETATE, ANHYDROUS
Systematic Name English
DECADRON-LA
Brand Name English
FORTECORTIN (CRYSTAL SUSPENSION)
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 21-(ACETYLOXY)-9-FLUORO-11,17-DIHYDROXY-16-METHYL-, (11.BETA.,16.ALPHA.)-
Systematic Name English
DEXAMETHASONE ACETATE [WHO-IP]
Common Name English
BETAMETHASONE ACETATE IMPURITY B [EP IMPURITY]
Common Name English
DEXAMETHASONE 21-ACETATE
MI  
Common Name English
DECTANCYL
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C521
Created by admin on Fri Dec 15 16:09:28 UTC 2023 , Edited by admin on Fri Dec 15 16:09:28 UTC 2023
Code System Code Type Description
RS_ITEM_NUM
1176506
Created by admin on Fri Dec 15 16:09:28 UTC 2023 , Edited by admin on Fri Dec 15 16:09:28 UTC 2023
PRIMARY
PUBCHEM
236702
Created by admin on Fri Dec 15 16:09:28 UTC 2023 , Edited by admin on Fri Dec 15 16:09:28 UTC 2023
PRIMARY
EPA CompTox
DTXSID8022901
Created by admin on Fri Dec 15 16:09:28 UTC 2023 , Edited by admin on Fri Dec 15 16:09:28 UTC 2023
PRIMARY
ECHA (EC/EINECS)
214-646-8
Created by admin on Fri Dec 15 16:09:28 UTC 2023 , Edited by admin on Fri Dec 15 16:09:28 UTC 2023
PRIMARY
WIKIPEDIA
Dexamethasone acetate
Created by admin on Fri Dec 15 16:09:28 UTC 2023 , Edited by admin on Fri Dec 15 16:09:28 UTC 2023
PRIMARY
DAILYMED
K7V8P532WP
Created by admin on Fri Dec 15 16:09:28 UTC 2023 , Edited by admin on Fri Dec 15 16:09:28 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DEXAMETHASONE ACETATE ANHYDROUS
Created by admin on Fri Dec 15 16:09:28 UTC 2023 , Edited by admin on Fri Dec 15 16:09:28 UTC 2023
PRIMARY Description: A white or almost white powder, odourless.Solubility: Practically insoluble in water; soluble in 40 parts of ethanol (~750 g/l) TS; slightly soluble in ether R. Category: Adrenoglucocorticoid. Storage: Dexamethasone acetate should be kept in a tightly closed container, protected from light. Labelling: The designation on the container of Dexamethasone acetate should state whether the substance is the monohydrateor is in the anhydrous form.
FDA UNII
K7V8P532WP
Created by admin on Fri Dec 15 16:09:28 UTC 2023 , Edited by admin on Fri Dec 15 16:09:28 UTC 2023
PRIMARY
MERCK INDEX
m4215
Created by admin on Fri Dec 15 16:09:28 UTC 2023 , Edited by admin on Fri Dec 15 16:09:28 UTC 2023
PRIMARY Merck Index
CAS
1177-87-3
Created by admin on Fri Dec 15 16:09:28 UTC 2023 , Edited by admin on Fri Dec 15 16:09:28 UTC 2023
PRIMARY
SMS_ID
100000092167
Created by admin on Fri Dec 15 16:09:28 UTC 2023 , Edited by admin on Fri Dec 15 16:09:28 UTC 2023
PRIMARY
RXCUI
2378841
Created by admin on Fri Dec 15 16:09:28 UTC 2023 , Edited by admin on Fri Dec 15 16:09:28 UTC 2023
PRIMARY
NCI_THESAURUS
C77000
Created by admin on Fri Dec 15 16:09:28 UTC 2023 , Edited by admin on Fri Dec 15 16:09:28 UTC 2023
PRIMARY
NSC
39471
Created by admin on Fri Dec 15 16:09:28 UTC 2023 , Edited by admin on Fri Dec 15 16:09:28 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SOLVATE->ANHYDROUS
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY